This study is a prospective, non-interventional, multi-center observational study to evaluate the efficacy and safety of Baroezet Tablet 1/10 mg in Korean patients with dyslipidemia in real-world clinical practice.
Patients who are prescribed Baroezet Tablet according to the physician's clinical judgment will be followed for approximately 24 weeks. The study will assess changes in lipid profiles, including LDL-C, as well as safety outcomes such as adverse events.
Adults aged ≥19 years
Patients diagnosed with dyslipidemia
Patients who require treatment with Baroezet Tablet
Patients who provide written informed consent
Hypersensitivity to study drug components
Active liver disease
Pregnant or breastfeeding women
Patients considered inappropriate by investigator
Daewoong Pharmaceutical Co. LTD.
Lead sponsor